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Purpose: The aim of the present study was to investigate the HLA phenotype in Dupuytren’s 
contracture (DC) patients in order to verify the correlation of these alleles with risk factors 
for development of DC in the Brazilian population. 
Methods: This was a case-controlled study of 25 DC patients and 443 healthy individuals 
with no history of HLA-associated diseases. HLA class I and class II typing was performed 
using the polymerase chain reaction sequence-specific primer method. Results: The HLA-
B*18 phenotype was observed in 32% of the patients and 10.5% of controls. However, P 
values did not remain significant after correction. 
Discussion: Although we observed an increased tendency of DC patients to possess the 
HLA-B*18 allele, the results were not statistically significant after correction. This allele was 
higher in patients of Italian and/or Spanish ethnicity, localities with frequencies higher 
than 18.0% and 14.0% respectively. Further investigation with a larger cohort of DC patients 
is required to confirm the potential role of HLA in this disease.
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Introduction 
Dupuytren's contracture (DC) is a connective tissue disease 
that presents abnormal fibroblastic proliferation of the pal-
mar fascia. It is characterized by the formation of nodules and 
fibrous cords causing longitudinal digital contracture. This 
leads to deformities that determine the characteristic ana-
tomical features of the disease and, in an advanced stage, can 
cause loss of motor function of the hand.1,2 Although there 
is a high rate of recurrence of the lesions, the most effective 
treatment is surgical excision.3 Many risk factors have been 
associated with DC, such as smoking, alcohol, local trauma, 
epilepsy, and diabetes mellitus.4-7 The incidence of DC is high-
er in Caucasians of European origin, predominantly affecting 
men over 50-years old.5 An autoimmune component for DC 
was proposed in 1972, and studies have confirmed the pres-
ence of antibody anti-collagen, but to date the exact etiology 
of DC has remained unknown.8-10 
Genetic susceptibility to DC is supported by epidemiologi-
cal observations, as its prevalence is quite high in people of 
Northern European origin and is only rarely seen in African 
and Asian populations. Observations from twin and family 
studies, examining Dupuytrens diathesis, in particular, have 
also supported a genetic basis.11,12 Several studies were per-
formed to identify candidate genes for susceptibility to DC, in-
cluding the cytokine transforming growth factor-β (TGF-β)13-15; 
the transcription factors Zf916, Mafb17 and Zic118; matrix me-
talloproteinases (MMPs)19; and nucleotide oligomerization 
domain/caspase recruitment domain (NOD/CARD) genes.20 
Although there is evidence of genetic predisposition to DC 
development, no susceptibility gene has been recognized as 
a risk factor for the disease. It is unclear whether DC is a sim-
ple monogenic Mendelian disorder or a complex oligogenic 
condition10. Due to the late onset of symptoms, it is difficult 
to observe the positive family history in many patients, sug-
gesting that the role of genetics in DC can be greater than the 
observed.16,21
After the discovery and description of the functions of the 
Major Histocompatibility Complex (MHC), Histocompatibility 
Leukocyte Antigens (HLA) in humans, several associations 
with different diseases have been described, which are linked 
to particular characteristics of this complex. The MHC is the 
most polymorphic genetic system in the human genome that 
participates in antigen presentation to T lymphocytes. The T 
cells are activated by specific peptides presented by HLA mol-
ecules, resulting in a specific immune response. Variations in 
responses to antigens have implicated the MHC as a factor 
in disease susceptibility.10,22 MHC diversity does not change 
over time in an individual, but alleles may differ significantly 
between individuals, making the MHC complex a promising 
biomarker target.20 Regarding this, studies have associated 
autoantibodies with variation in genes involved in antigen 
presentation. Pereira et al. reported that auto-antibodies 
to denatured collagen type II were more prevalent in HLA-
DR4-positive DC patients than in the control population.23 In 
contrast, Neumüller et al. found the association of HLA-DR3 
and auto-antibodies in the connective tissue of DC patients.24 
However, Spencer et al. observed a higher (not statistically 
significant) incidence of HLA-DR4 in individuals with DC than 
in those without it. They also found that HLA-DR3-positive DC 
patients almost always carried HLA-A1 and HLA-B8 alleles, 
indicating that the HLA A1-B8-DR3 haplotype, which has also 
been associated with other autoimmune disorders, could be 
important in DC.25 These results provided evidence of an im-
munogenic component, although no specific HLA allele has 
been linked to the disease.
The recent study by Brown et al. revealed significant asso-
ciation of the frequency of HLA-DRB1*15 with the pathogen-
esis of DC in Caucasian patients of European origin.10
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Objetivo: O objetivo deste estudo foi investigar o fenótipo do HLA em pacientes com con-
tratura de Dupuytren (CD) para verificar a correlação desses alelos com os fatores de risco 
para o desenvolvimento da CD na população brasileira. 
Métodos: Este foi um estudo de caso-controle de 25 pacientes com CD e 443 indivíduos 
saudáveis sem histórico de doenças associadas ao HLA. As tipagens classe I e classe II do 
HLA foram feitas utilizando o método iniciador de sequências específicas da reação em 
cadeia da polimerase. Resultados: O fenótipo HLA-B*18 foi observado em 32% dos pacien-
tes e 10,5% do grupo controle. Contudo, os valores de p não permaneceram significativos 
após correção. 
Discussão: Apesar de termos observado um aumento na tendência de os pacientes com 
CD terem o alelo HLA-B*18, os resultados não foram estatisticamente significativos após 
correção. Esse alelo foi maior em pacientes de etnia italiana e/ou espanhola, locais com 
frequências superiores a 18% e 14%, respectivamente. São necessárias investigações adi-
cionais com uma coorte maior de pacientes com CD para confirmar o possível papel do 
HLA nessa doença.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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Although the above results are controversial, the literature 
suggests that this disease is multifactorial in origin, with fa-
milial traits. There are no genetic studies of DC in the Brazil-
ian population, which is characterized by major miscegena-
tion according to Parra et al.26 Thus, the purpose of this study 
was to identify the frequency of HLA class I (loci A* and B*) 
and class II (loci DRB1* and DQB1*) in DC patients in the Bra-
zilian population in a case-controlled model and to investi-
gate HLA allele as a risk factor for disease development. 
Methods 
Patients and controls
Twenty-five unrelated patients diagnosed with DC (17 men 
and 8 women), with a mean age of 54.24 years (range: 40–70 
years old) from Bauru and Jaú cities of São Paulo State-SP, 
Southeast of Brazil, were enrolled in this study. The classifi-
cation of ancestry was based on the phenotype through in-
terviews in the approach to patients. The sample size calcu-
lation was not applied, due the rarity of this disease in the 
population studied, thus all of the patients with DC and who 
agreed to participate were included in the study. All of them 
were diagnosed by physicians specialized in hand surgery at 
the Lauro de Souza Lima Research Institute (ILSL), Bauru-SP. 
The control group was composed of 443 healthy individuals 
with no history of HLA-associated diseases (200 men and 243 
women), with a mean age of 37.65 years (range: 20-68 years 
old). They were matched for ethnic background and other de-
mographic patterns. All samples were typed at the Immuno-
genetics Laboratory of the ILSL, after the participants signed 
informed consent forms, and the study was approved by the 
ILSL’s Ethics Committee on research involving human beings.
Typing of the HLA alleles
 Genomic DNA was extracted using the salting-out method.27 
The HLA alleles, class I locus A* (A*01-74) and B* (B*07-81), 
class II DRB1* locus (DRB1*01-18), and DQB1* (DQB1*02-09) 
were typed using the polymerase chain reaction sequence-
specific primer (One-Lambda, Canoga Park, CA, USA).
Statistical analysis
HLA class I and class II alleles were counted to determine al-
lelic frequencies. The distribution of these frequencies was 
evaluated for Hardy–Weinberg disequilibrium using Arlequin 
software, version 3.1.28
The analysis of associations of HLA with DC was achieved 
using the chi-square test with Yates’ correction or Fisher’s 
exact test. P-values ≤ 0.05 were considered statistically sig-
nificant. Odds ratio (OR) was calculated with a 95% confidence 
interval (95% CI). P values were corrected (Pc) by multiplying 
the P value by the number of antigens tested (Bonferroni test), 
with 5% significance level, using the statistical program SISA 
(http://home.clara.net/sisa/). The power of the study was 
calculated using the software OpenEpi version 3 with bilat-
eral confidence interval of 95% (http://www.openepi.com/v37/
Power/PowerCC.htm). 
Results 
This study compared HLA allele frequencies of DC patients 
with healthy controls in a southeast region of Brazil.
Table 1 shows that 68% (17) of the patients were men and 
these 76.5% (13) were aged 50 years or older. Manifestation of 
DC in men was at a mean age of 52 years (range: 40–63 years 
old) while disease onset occurred latter in women, with the 
mean age of 57.9 years (range: 46–74 years old). With respect 
to manual activities, 68% (17) of patients reported high lev-
els of moderate-to-heavy activities. From the total of patients 
studied, 44% (11) had both their hands affected by the disease, 
and from these 63.6% (7) were men. Of the 25 patients, 24 were 
of European ancestry, with 70.8% being of Italian descent (17).
Direct counting provided the frequency of class I and class 
II alleles, and their distribution was confirmed by the Hardy–
Weinberg equilibrium using Arlequin 3.1 software. The HLA 
class I and class II allele frequencies in both DC and the con-
trol group are showed in Table 2-5. For the majority of HLA-
A,-B, DR and DQ allele frequencies were found to be similar 
in both groups. However the frequency of HLA-B*18 allele was 
found in 32.0 % (8) of the 25 of DC patients compared to 10.5% 
(46) of the non-affected controls (P = 0.003, OR: 4.02 and CI 
95%: 1.64–9.83), although  P values were not significant after 
correction by Bonferoni test multiplying the P value by the 
number of antigens, as shown in Table 3. 
Discussion 
Although DC has been described for centuries, its etiology 
and pathology remain poorly understood.29 To date, several 
environmental risk factors have been implicated in DC, in-
cluding smoking, alcohol intake, diabetes, epilepsy, and trau-
ma. Many patients with DC believe that their condition was 
caused by heavy labor or trauma. Dupuytren, himself, initially 
believed this to be the cause of the disease because many of 
the patients he studied were laborers.12 In the present study, 
moderate-to-heavy manual activity was predominant. 
Epidemiological studies indicate a high prevalence of DC 
among Northern European Caucasian men aged 50 years or 
older, and this is cited as the most common inherited con-
nective tissue disorder in this population.2,9,30 Previous stud-
ies have shown that men are more commonly affected than 
women, with the disease presenting at an earlier age. Our 
study also found that most patients were men aged above 50 
years, and the mean age of disease manifestation in women 
was higher than in men, furthermore bilateral disease were 
more common in men, in agreement with the literature.31
Although there is evidence of genetic involvement on the 
onset of DC, there is no consensus regarding the specific role 
of genetics in susceptibility to DC. To date, no specific gene 
has been described as a risk factor for this disease, although 
some studies have been conducted to elucidate the role of ge-
netics in the immunopathogenesis of the disease.10,32,33 
Currently, it is known that T lymphocytes recognize anti-
gens when presented with HLA molecules on the surface of 
antigen presenting cells, where a specific immune response is 
initiated, such as the production of interleukins, proliferation, 
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Table 3 – HLA-B* allele frequency in patients with 
Dupuytren´s contracture and control group.
Alleles Dupuytren´s 
contracture (N = 25)
Control group (N 
= 443)
p
n Fa (%) n Fa (%)
B*07 01 4.0 57 13.0 0.122
B*08 05 20.0 50 11.3 0.099
B*13 01 4.0 10 2.3 0.346
B*18 08 32.0 46 10.5 0.003 a
B*27 01 4.0 18 4.1 0.385
B*35 04 16.0 104 23.5 0.142
B*37 00 0.0 10 2.3 0.571
B*38 01 4.0 23 5.2 0.368
B*39 04 16.0 20 4.5 0.082
B*41 00 0.0 14 3.2 0.455
B*42 00 0.0 10 2.3 0.571
B*44 04 16.0 85 19.2 0.199
B*45 00 0.0 14 3.2 0.455
B*46 01 4.0 00 0.0 0.060
B*47 00 0.0 01 0.2 0.946
B*48 00 0.0 01 0.2 0.946
B*49 02 8.0 25 5.7 0.263
B*50 00 0.0 21 4.8 0.304
B*51 04 16.0 79 17.8 0.211
B*52 02 8.0 28 6.4 0.278
B*53 00 0.0 12 2.7 0.510
B*54 00 0.0 00 0.0 1.000
B*55 00 0.0 15 3.4 0.430
B*56 00 0.0 02 0.4 0.895
B*57 01 4.0 13 3.0 0.374
B*58 00 0.0 06 1.4 0.715
B*60 01 4.0 18 4.1 0.385
B*61 01 4.0 15 3.4 0.383
B*62 02 8.0 33 7.5 0.289
B*63 01 4.0 15 3.4 0.383
B*64 00 0.0 09 2.0 0.604
B*65 02 8.0 38 8.6 0.287
B*70 01 4.0 23 5.2 0.368
B*75 00 0.0 01 0.2 0.946
B*76 00 0.0 00 0.0 1.000
B*81 00 0.0 07 1.6 0.676
Blank 04 16.0 55 12.5 0.195
N, number of individuals; n, number of alleles; Fa, frequency of 
alleles; p value - Fisher test p ≤ 0.05.
a Odds Ratio (OR): 4.02,  Confidence Interval (IC 95%): 1.64-9.83, 
Pcorrected (Pc) = 0.11.
and control of effector molecules, and regulatory functions of 
lymphocytes.34 
Nowadays, many diseases have established genetic links 
with the HLA complex, such as narcolepsy and HLA-DR2, 
rheumatoid arthritis and HLA-DR4 35,36, hemochromatosis 
and HLA-A3, psoriasis and HLA-Cw637, multiple sclerosis and 
HLA-DR2, and celiac disease and HLA-DR3.38 The mechanisms 
of these associations with the particular alleles are still not 
fully understood. It is believed that for some of these diseases 
there is a failure in the expression of the HLA molecule, re-
sulting in disabled molecules. In other cases, defects in other 
genes may influence the expression of HLA molecules on the 
cell surface.39,40 
According to Ottenhoff et al.,41 the same antigens are rec-
ognized in individuals who fall ill and healthy individuals, but 
there are differences in the ability of the individuals to re-
Table 1 – Characterization of patients with Dupuytren´s 
contracture in the study.
Patient Gender Age Ocupation Ancestry
1 M 40 cutlery Spanish
2 M 50 farmer Portuguese
3 Fa 49 housewife German/
Portuguese
4 M 46 farmer Italian
5 M 50 professor Portuguese
6 Ma 43 driver German/Italian
7 M 50 bricklayer Spanish
8 M 55 economist Italian/Spanish
9 M 55 machine 
operator
Italian/Brazilian
10 Fa 63 housewife Brazilian
11 F 46 sales 
representative
Italian/Portuguese
12 M 63 farmer Italian/Portuguese
13 F 74 farmer Italian/Brazilian
14 Ma 55 businessman Italian/Brazilian
15 Fa 57 housewife Italian
16 F 64 housewife Italian
17 M 58 farmer Italian/Spanish
18 F 47 shoemaker Italian/Brazilian
19 Ma 46 guard Italian
20 M 63 businessman Spanish
21 F 63 housewife Italian
22 Ma 57 driver Italian
23 Ma 50 vigilant German
24 Ma 51 banking Italian/Chinese
25 Ma 52 designer Italian/Brazilian
M, male; F, female.
a Bilateral disease. 
Table 2 – HLA-A* allele frequency in patients with 
Dupuytren´s contracture patients and control group.
Alleles Dupuytren´s 
contracture (N = 25)
Control group  
(N = 443)
p
n Fa (%) n Fa (%)
A*01 08 32.0 79 18.0 0.107
A*02 07 28.0 203 46.0 0.098
A*03 02 8.0 71 16.0 0.142
A*11 04 16.0 47 10.7 0.163
A*23 00 0.0 44 10.0 0.077
A*24 07 28.0 66 15.0 0.089
A*25 02 8.0 15 3.4 0.174
A*26 00 0.0 40 9.1 0.098
A*29 03 12.0 41 9.3 0.225
A*30 03 12.0 51 11.5 0.245
A*31 00 0.0 33 7.5 0.150
A*32 04 16.0 25 5.7 0.060
A*33 00 0.0 24 5.5 0.255
A*34 00 0.0 07 1.6 0.676
A*36 01 4.0 04 0.9 0.217
A*66 01 4.0 07 1.6 0.296
A*68 02 8.0 46 10.4 0.265
A*69 00 0.0 00 0.0 1.000
A*74 00 0.0 01 0.2 0.946
Blank 06 24.0 71 16.0 0.118
N, number of individuals; n, number of alleles; Fa, frequency of 
alleles; p value, Fisher test p ≤ 0.05.
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Table 5 – HLA-DQB1* allele frequency in patients with 
Dupuytren´s contracture and control group.
Alleles Dupuytren´s 
contracture (n = 25)
Control group  
(n = 443)
p
n Fa (%) n Fa (%)
DQB1*02 12 48.0 180 40.7 0.125
DQB1*04 03 12.0 56 12.7 0.243
DQB1*05 09 36.0 154 34.8 0.167
DQB1*06 10 40.0 213 48.2 0.121
DQB1*07 11 44.0 147 33.2 0.090
DQB1*08 03 12.0 41 9.3 0.224
DQB1*09 02 8.0 12 2.7 0.135
N, number of individuals; n, number of alleles; Fa, frequency of 
alleles; p value-Fisher test p ≤ 0,05.
Table 4 – HLA-DRB1* allele frequency in patients with 
Dupuytren´s contracture and control group.
Alleles Dupuytren´s 
contracture (N = 25)
Control group 
(N = 443)
p
n Fa (%) n Fa (%)
DRB1*01 03 12.0 83 18.7 0.164
DRB1*04 05 20.0 85 19.2 0.200
DRB1*07 07 28.0 107 24.2 0.164
DRB1*08 03 12.0 55 12.4 0.244
DRB1*09 00 0.0 14 3.2 0.458
DRB1*10 00 0.0 22 5.0 0.290
DRB1*11 10 40.0 123 27.8 0.073
DRB1*12 00 0.0 14 3.2 0.458
DRB1*13 05 20.0 112 25.3 0.166
DRB1*14 02 8.0 34 7.7 0.289
DRB1*15 07 28.0 76 17.2 0.078
DRB1*16 02 8.0 32 7.2 0.287
DRB1*17 05 20.0 69 15.6 0.172
DRB1*18 01 4.0 10 2.3 0.344
N, number of individuals; n, number of alleles; Fa, frequency of 
alleles; p value - Fisher test p ≤ 0,05.
spond to these proteins. It is known that HLA varies according 
to patients’ ethnicity and geographic location. Brazil shows 
an extremely mixed ethnicity spread across a large geograph-
ic region. Because of these peculiarities, it is extremely im-
portant to study the correlation of HLA alleles and DC in this 
population.42
Discordant or non-replicated results for the association of 
HLA with DC appear in the literature. Shih et al.29 suggested a 
possible role of the ancestral haplotype HLA A1-B8-DR3 in DC. 
Studies by Neumüller et al.24 and Brown et al.10 describe that 
HLA-DR3 and HLA-DRB1*15 respectively are risk factors for 
DC; however, this genetic association has not yet been patho-
physiologically explained.
The results of the present study do not confirm the find-
ings described above, once we found increased of the HLA-B 
*18 in patients with DC when compared to the low incidence 
in the control group in a Brazilian population. Although these 
data lose significance after statistical correction, the in-
creased frequency of this allele in individuals with DC should 
not be neglected, given the small number of patients studied. 
However, these results cannot be interpreted as lack of effect 
since the study had a power of 100%. 
The disagreement between the results obtained in this 
study and the literature data may originate from the genetic 
background of patients, as well as the different ethnic groups 
and geographic regions studied, as also the technique used to 
determine the HLA specificities.42
The HLA-B* 18 allele is found in Italian and Spanish popu-
lation with a frequency higher than 18.0% and 14.0%, respec-
tively, however in the Brazilian population this allele is ob-
served only in 8.0%.43 It is interesting to note that of the 25 
patients studied, 20 were of Italian and/or Spanish descent, 
which could suggest an association of ethnicity with a higher 
incidence of this disease, although our results do not show a 
strong association of this allele with DC. 
Future studies with a larger cohort of DC patients could 
confirm the potential role of HLA in this disease and help to 
understand the immunopathogenesis as well as to contribute 
for the development of models for diagnosis, prevention, and 
appropriate treatment regimens for patients.
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